ICARA Criteria (Elan, Bapineuzumab for Alzheimer treatment)

Inclusion criteria:

·  Written informed consent of patient (and caregiver)

·  Age 50 < 89 yrs.

·  Diagnosis of probable AD according to NINCDS/ADRDA criteria

·  MMSE between 16-26 (inclusive)

·  Lives with caregiver or has caregiver that sees patients approx. 5 times a week and caregiver is able to accompany patient on all clinic visits

·  Fluent in English

·  Patient has adequate visual and auditory abilities for cognitive/functional assessment

·  Willing to undergo ApoE testing and OK with disclosure of ApoE4 status

Exclusion criteria:

·  Significant neurological/psychiatric disease/disorder other than AD that affects cognition

·  Weight > 120 kg (264 lbs)

·  History of clinically evident stroke or other abnormalities as evidenced by MRI

·  Uncontrolled hypertension within the last 6 months

·  Excessive smoking > 20 cigarettes per day

·  History of alcohol or drug dependence or abuse within the last 2 years (DSM-IV)

·  Women of childbearing potential

·  Presence of pacemakers, aneurysm clips etc. that would contraindicate MRI

ADNI-GO Criteria (Avid-45 PET brain imaging)

Inclusion criteria:

·  - 55-90 years of age

·  - study partner

·  - must speak English

·  - memory complaint

·  - absence of significant levels of impairment in other cognitive domains

·  - absence of dementia

·  - neuropsych testing: MMSE score 24-30; objective memory loss measured by education adjusted scores on Logical Memory II; CDR of 0.5

·  - geriatric depression scale less than 6

·  - stability of medications for at least 4 weeks

Exclusion criteria:

·  - any significant neurological disease other than MCI

·  - presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, or any metal fragments implanted in body

·  - major depression, bipolar disorder within past year

·  - history of schizophrenia

·  - any systemic illness or medical condition that could interfere which could lead to difficulty complying with protocol

·  - clinically significant abnormalities in B12

·  - residence in skilled nursing facility

·  - current use of psychoactive medications ( certain antidepressants, neuroleptics, chronic anxiolytics or sedative hypnotics)

·  - current use of warfarin (exclusionary for lumbar puncture)

·  - participation in clinical studies involving neuropsychological measures being collected more than once per year

·  - participation in clinical drug trials within last month

·  - current of recent participation in any procedures involving radioactive agents such that the total radiation dose exposure to the subject in any given year would exceed annual limits

CITAD Criteria (Probable Alzheimer’s disease with agitation)

Inclusion criteria:

·  Probable AD with MMSE score of 5-26

·  A medication for agitation is appropriate, in the opinion of the study physician

·  Clinically significant agitation for which either

1)  the frequency of agitation as assessed by the NPI is 'Very frequently', or

2)  the frequency of agitation as assessed by the NPI is 'Frequently' AND the severity of the agitation as assessed by the NPI is 'Moderate', or 'Marked'

·  Availability of primary caregiver, who spends several hours a week with the patient and supervises his/her care, to accompany the patient to study visits and to participate in the study.

·  Able to communicate (written & spoken) in English from patient or cg

·  If on TX for AD, stability of TX (i.e., memantine or cholinesterase inhibitors),

no changes to AD medications (e.g., starting or stopping treatment) in the 3 months prior to randomization,

with the exception that dose adjustments within the therapeutic range

(i.e., total daily dose of ≥ 10 mg of memantine, ≥ 5mg of donepezil, ≥ 16mg per day of galantamine, or

≥ 4mg per day of rivastigminc) are allowed as long as:

1) The patient has received the minimum therapeutic range dose or higher for at least 3 months;

2) The last dose change was at least I month prior to randomization; and

3) No further dose adjustments are planned during the study's treatment phase

Exclusion criteria:

·  Meets criteria for Major Depressive Episode by DSM-TV (TR) criteria

·  Presence of a brain disease that might otherwise explain the presence of dementia, such as extensive brain vascular disease, PD, dementia with Lewy bodies, TBI, or multiple sclerosis

·  Psychosis (delusions or hallucinations requiring antipsychotic treatment in the opinion of the study physician)

·  Treatment with citalopram is contraindicated in the opinion of the study physician

·  Failure of past TX with citalopram for agitation after at least a 3 week trial at a minimally accepted dose (20mg/day or higher)

·  TX with a medication that could prohibit the safe concurrent use of citalopram, such as MAO inhibitors

·  Need for psychiatric hospitalization, or suicidal

·  Current participation in a clinical trial or in any study that may acid a significant burden or affect neuropsychological or other study outcomes

·  Current TX with antipsychotics, anticonvulsants, other antidepressants (other than trazodone, ≤50 mg/day @bedtime, benzodiazepines (other than 0 .5 mg/day Lorazepam), or psycho stimulants

Any condition, in the opinion of the study physician, makes it medically inappropriate for the patient to enroll in the